All In Biotech

Drug Trial Radar · NCT01970098

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Last checked: Nov 19, 2026Latest source record: Dec 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 374 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

374

Actual

Start

Oct 9, 2013

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Sponsor type
Industry
First posted
Oct 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.

Conditions

  • Spinocerebellar Degeneration

Interventions

  • KPS-0373, High doseDrug

    28 weeks

  • KPS-0373, Low doseDrug

    28 weeks

  • PlaceboDrug

    28 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SARA (Scale for the Assessment and Rating of Ataxia)Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Multiple Locations, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.